Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

143.45 -0.90 (-0.62%)
Streaming Delayed Price Updated: 2:24 PM EDT, Jul 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
From BeiGene
Via Business Wire
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
From BeiGene
Via Business Wire
Recap: BeiGene Q1 Earnings
Via Benzinga
BeiGene's Tislelizumab/Chemo Combo Hits Primary Goal In Gastric Cancer Study
Via Benzinga
Why BeiGene Stock Jumped Thursday
A collaboration deal helped send the Chinese biotech stock higher. 
Via The Motley Fool
Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
Via Benzinga
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor... 
Via Benzinga
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
From BeiGene
Via Business Wire
Beigene Ltd. (NASDAQ: BGNE) Highlighted for Surprising Price Action
Via Investor Brand Network
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
From BeiGene
Via Business Wire
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
From BeiGene, Ltd.
Via Business Wire
What's Going On With Immix Biopharma Stock Today
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG' 
Via Benzinga
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
From BeiGene
Via Business Wire
3 Top Biotech Stocks Defying the Bear Market
All three companies have therapies with strong sales potential. 
Via The Motley Fool
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
From BeiGene
Via Business Wire
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
From BeiGene
Via Business Wire
7 Biotech Stocks That Could Cure Your Portfolio Woes
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
From BeiGene, Ltd.
Via Business Wire
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
From BeiGene
Via Business Wire
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials
This month, H.C. Wainwright & Co. 
Via Benzinga
BeiGene Expands Presence in Latin America With Opening of Brazil Office
From BeiGene
Via Business Wire
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global... 
Via Benzinga
Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors
This month, Enlivex Therapeutics Ltd. 
Via Benzinga
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
From BeiGene
Via Business Wire
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
From BeiGene
Via Business Wire
Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.